Search Orphan Drug Designations and Approvals
-
Generic Name: | teduglutide [rDNA origin]; teduglutide [rDNA origin] | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | GATTEX; GATTEX | ||||||||||||||||
Date Designated: | 06/29/2000 | ||||||||||||||||
Orphan Designation: | Treatment of short bowel syndrome. | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Takeda Pharmaceuticals U.S.A., Inc. 95 Hayden Avenue Lexington, Massachusetts 02421 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | teduglutide [rDNA origin]; teduglutide [rDNA origin] |
---|---|---|
Trade Name: | GATTEX; GATTEX | |
Marketing Approval Date: | 12/21/2012 | |
Approved Labeled Indication: | Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support | |
Exclusivity End Date: | 12/21/2019 | |
Exclusivity Protected Indication* : | ||
2 | Generic Name: | teduglutide [rDNA origin]; teduglutide [rDNA origin] |
---|---|---|
Trade Name: | GATTEX; GATTEX | |
Marketing Approval Date: | 05/16/2019 | |
Approved Labeled Indication: | GATTEX® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. | |
Exclusivity End Date: | 05/16/2026 | |
Exclusivity Protected Indication* : | Treatment of pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-